Age, Biography and Wiki
Jeffery W. Kelly was born on 23 August, 1960 in Medina, New York, United States. Discover Jeffery W. Kelly's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is He in this year and how He spends money? Also learn how He earned most of networth at the age of 63 years old?
| Popular As | N/A |
| Occupation | N/A |
| Age | 63 years old |
| Zodiac Sign | Leo |
| Born | 23 August, 1960 |
| Birthday | 23 August |
| Birthplace | Medina, NY |
| Nationality | United States |
We recommend you to check the complete list of Famous People born on 23 August. He is a member of famous with the age 63 years old group.
Jeffery W. Kelly Height, Weight & Measurements
At 63 years old, Jeffery W. Kelly height not available right now. We will update Jeffery W. Kelly's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.
| Physical Status | |
|---|---|
| Height | Not Available |
| Weight | Not Available |
| Body Measurements | Not Available |
| Eye Color | Not Available |
| Hair Color | Not Available |
Dating & Relationship status
He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.
| Family | |
|---|---|
| Parents | Not Available |
| Wife | Not Available |
| Sibling | Not Available |
| Children | Not Available |
Jeffery W. Kelly Net Worth
His net worth has been growing significantly in 2022-2023. So, how much is Jeffery W. Kelly worth at the age of 63 years old? Jeffery W. Kelly’s income source is mostly from being a successful . He is from United States. We have estimated Jeffery W. Kelly's net worth , money, salary, income, and assets.
| Net Worth in 2023 | $1 Million - $5 Million |
| Salary in 2023 | Under Review |
| Net Worth in 2022 | Pending |
| Salary in 2022 | Under Review |
| House | Not Available |
| Cars | Not Available |
| Source of Income |
Jeffery W. Kelly Social Network
Timeline
Kelly was elected as a fellow of the National Academy of Inventors (2017), as a Fellow of the Royal Society of Chemistry (2017), as a member of the American Academy of Arts and Sciences (2016), delivered the commencement address at SUNY Fredonia (2016), and has won numerous awards including the American Institute of Chemists Chemical Pioneer Award, 2017; the Jacob Heskel Gabbay Award in Biotechnology and Medicine, 2016; the Royal Society of Chemistry Jeremy Knowles Award, 2016; the Biopolymers Murray Goodman Memorial Prize, 2012; the American Chemical Society, Ralph F. Hirschmann Award in Peptide Chemistry, 2012; the Protein Society Emil T. Kaiser Award, 2011; the American Peptide Society Rao Makineni Lectureship (Award), 2011; the American Peptide Society Vincent du Vigneaud Award, 2008; the National Institutes of Health Merit Award, 2006; the American Chemical Society Arthur C. Cope Scholar Award, 2001; the SUNY at Fredonia Alumni Distinguished Achievement Award, 2000; the SUNY at Fredonia Chemistry Dept. Alumni Award, 2000; the Protein Society-Dupont Young Investigator Award, 1999; the Biophysical Society National Lecturer (Award), 1999; and the Searle Scholar Award, 1991.
Kelly has cofounded three biotechnology companies, FoldRx Pharmaceuticals with Susan Lindquist in 2003, Proteostasis Therapeutics, Inc. with Andrew Dillin and Richard Morimoto in 2010, and Misfolding Diagnostics in 2012.
He is former Dean of Graduate Studies (2000-2008) and Vice President of Academic Affairs (2000-2006) and co-Chairman of Molecular Medicine and the Lita Annenberg Hazen Professor of Chemistry within the Skaggs Institute of Chemical Biology at The Scripps Research Institute in La Jolla, California. His research focuses on understanding protein folding, misfolding and aggregation and on developing both chemical and biological strategies to ameliorate diseases caused by protein misfolding and/or aggregation.
His lab began looking for ways to inhibit transthyretin fibril formation in the 1990s. Tafamidis was eventually discovered by Kelly's team using a structure-based drug design strategy; the structure was first published in 2003. In 2003 Kelly co-founded FoldRx with Susan Lindquist of MIT and the Whitehead Institute and FoldRx developed tafamidis up through submitting an application for marketing approval in Europe in early 2010. FoldRx was acquired by Pfizer later that year.
Kelly received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill (1986) and performed post-doctoral research at The Rockefeller University (1986–89).
Jeffery W. Kelly (born August 23, 1960 in Medina, New York) is an American chemist and entrepreneur who is on the faculty of the Scripps Research Institute in La Jolla, California.
